Am. J. Respir. Crit. Care Med., Volume 162, Number 2, August 2000, 603-611

A Small-Molecule, Tight-binding Inhibitor of the Integrin ₄₁ Blocks Antigen-induced Airway Responses and Inflammation in Experimental Asthma in Sheep

WILLIAM M. ABRAHAM, ALAN GILL, ASHFAQ AHMED, MAREK W. SIELCZAK, ISABEL T. LAUREDO, YELENA BOTINNIKOVA, KO-CHUNG LIN, BLAKE PEPINSKY, DIANE R. LEONE, ROY R. LOBB, and STEVEN P. ADAMS

Division of Pulmonary Disease and Critical Care Medicine, University of Miami at Mount Sinai Medical Center, Miami Beach, Florida; and Biogen, Boston, Massachusetts

The leukocyte integrin very late antigen-4 (₄₁, CD49d/CD29) is an adhesion receptor that plays an important role in allergic inflammation and contributes to antigen-induced late responses (LAR) and airway hyperresponsiveness (AHR). In this study, we show that single doses of a new small-molecule, tight-binding inhibitor of ₄, BIO-1211, whether given by aerosol or intravenously, either before or 1.5 h after antigen challenge blocks allergen- induced LAR and post-antigen-induced AHR in allergic sheep. Multiple treatments with doses of BIO-1211 that were ineffective when given singly, were protective. BIO-1211 also provided dose-dependent inhibition of the early airway response (EAR) to antigen. In conjunction with the functional protection against the antigen-induced LAR and AHR, sheep treated with BIO-1211 before challenge showed significantly reduced: (1) numbers of eosinophils in bronchoalveolar lavage (BAL), (2) BAL levels of the inflammatory marker tissue kallikrein, and (3) numbers of inflammatory cells (lymphocytes, eosinophils, metachromatic staining cells, and neutrophils) in bronchial biopsies obtained after challenge when compared with corresponding biopsies after vehicle treatment. More importantly, we show for the first time that an inhibitor of ₄ was able to reverse post-antigen-induced AHR, thereby decreasing the time of recovery from the normal period of > 9 d to 3 d. Our results show that effective inhibition of antigen-induced airway responses can be achieved with single doses of a potent small-molecule inhibitor of ₄ and that such agents may be used therapeutically, as well as prophylactically, to alleviate allergen- induced inflammatory events. These data provide further support and extend the evidence for the role of ₄ integrins in the pathophysiologic events that follow airway antigen challenge.

This article has been cited by other articles:

				S. R. Barthel, M. W. Johansson, D. M. McNamee, and D. F. Mosher Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma J. Leukoc. Biol., January 1, 2008; 83(1): 1 - 12. [Abstract] [Full Text] [PDF]

				M. T. Kasaian, D. D. Donaldson, L. Tchistiakova, K. Marquette, X.-Y. Tan, A. Ahmed, B. A. Jacobson, A. Widom, T. A. Cook, X. Xu, et al. Efficacy of IL-13 Neutralization in a Sheep Model of Experimental Asthma Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 368 - 376. [Abstract] [Full Text] [PDF]

				W. M. Abraham, A. Ahmed, I. Serebriakov, I. T. Lauredo, J. Bassuk, J. A. Adams, and M. A. Sackner Whole-Body Periodic Acceleration Modifies Experimental Asthma in Sheep Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 743 - 752. [Abstract] [Full Text] [PDF]

				S. D. Rosen, D. Tsay, M. S. Singer, S. Hemmerich, and W. M. Abraham Therapeutic Targeting of Endothelial Ligands for L-selectin (PNAd) in a Sheep Model of Asthma Am. J. Pathol., March 1, 2005; 166(3): 935 - 944. [Abstract] [Full Text] [PDF]

				K. Yonekawa and J. M. Harlan Targeting leukocyte integrins in human diseases J. Leukoc. Biol., February 1, 2005; 77(2): 129 - 140. [Abstract] [Full Text] [PDF]

				W. M. Abraham, A. J. Bourdelais, J. R. Sabater, A. Ahmed, T. A. Lee, I. Serebriakov, and D. G. Baden Airway Responses to Aerosolized Brevetoxins in an Animal Model of Asthma Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 26 - 34. [Abstract] [Full Text] [PDF]

				I. T. Lauredo, R. M. Forteza, Y. Botvinnikova, and W. M. Abraham Leukocytic cell sources of airway tissue kallikrein Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L734 - L740. [Abstract] [Full Text] [PDF]

				W. M. Abraham, A. Ahmed, I. Serebriakov, A. N. Carmillo, J. Ferrant, A. R. de Fougerolles, E. A. Garber, P. J. Gotwals, V. E. Koteliansky, F. Taylor, et al. A Monoclonal Antibody to {alpha}1{beta}1 Blocks Antigen-induced Airway Responses in Sheep Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 97 - 104. [Abstract] [Full Text] [PDF]

				G. C. Koo, K. Shah, G. J. F. Ding, J. Xiao, R. Wnek, G. Doherty, X. C. Tong, R. B. Pepinsky, K.-C. Lin, W. K. Hagmann, et al. A Small Molecule Very Late Antigen-4 Antagonist Can Inhibit Ovalbumin-induced Lung Inflammation Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1400 - 1409. [Abstract] [Full Text] [PDF]

				G. J. Bellingan, P. Xu, H. Cooksley, H. Cauldwell, A. Shock, S. Bottoms, C. Haslett, S. E. Mutsaers, and G. J. Laurent Adhesion Molecule-dependent Mechanisms Regulate the Rate of Macrophage Clearance During the Resolution of Peritoneal Inflammation J. Exp. Med., December 2, 2002; 196(11): 1515 - 1521. [Abstract] [Full Text] [PDF]

				S. Tasaka, S. E. Richer, J. P. Mizgerd, and C. M. Doerschuk Very Late Antigen-4 in CD18-Independent Neutrophil Emigration during Acute Bacterial Pneumonia in Mice Am. J. Respir. Crit. Care Med., July 1, 2002; 166(1): 53 - 60. [Abstract] [Full Text] [PDF]

				E. Kudlacz, C. Whitney, C. Andresen, A. Duplantier, G. Beckius, L. Chupak, A. Klein, K. Kraus, and A. Milici Pulmonary Eosinophilia in a Murine Model of Allergic Inflammation Is Attenuated by Small Molecule alpha 4beta 1 Antagonists J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 747 - 752. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580. [Full Text] [PDF]